Group 1 - The Hong Kong stock market is experiencing fluctuations, with the innovative drug sector following the market's downward trend, as evidenced by the Hong Kong innovative drug ETF (159567) dropping over 3% [1] - Despite the market adjustments, the innovative drug sector has attracted attention, with the Hong Kong innovative drug ETF (159567) seeing an increase of 102 million shares, indicating a net inflow of funds for nine consecutive months, reaching a record high of 8.2 billion shares as of October 22 [1] - Recently, Innovent Biologics announced a global strategic partnership with Takeda Pharmaceutical to accelerate the development of its next-generation IO and ADC therapies, which includes an upfront payment of $1.2 billion and potential milestone payments totaling up to $10.2 billion, bringing the total deal value to a maximum of $11.4 billion [1] Group 2 - The Hong Kong innovative drug ETF (159567) tracks the Guozheng Hong Kong Stock Connect Innovative Drug Index, reflecting the performance characteristics of listed companies in the innovative drug sector within the Hong Kong Stock Connect [2] - Investors can also access the Hong Kong innovative drug sector through the Hong Kong innovative drug ETF linked funds (Class A: 023929, Class C: 023930) for potential upward opportunities in the sector [2]
创新药产业逐步迈入收获兑现期，港股创新药ETF（159567）昨日逆势获资金加仓，有望连续9个月获资金净流入
Mei Ri Jing Ji Xin Wen·2025-10-23 02:23